Dr. Scott Shofer
Claim this profileDurham VA Medical Center
Area of expertise
Lung Cancer
Scott Shofer has run 3 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Scott Shofer has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Durham VA Medical Center
Duke University Medical Center
Clinical Trials Scott Shofer is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Surgery vs Stereotactic Radiotherapy
for Lung Cancer
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Recruiting
1 award
N/A
16 criteria
More about Scott Shofer
Clinical Trial Related
11 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Scott Shofer has experience with
- Talc
- Biospecimen Collection
- Carboplatin
- Gemcitabine Hydrochloride
- Paclitaxel
- Pembrolizumab
Breakdown of trials Scott Shofer has run
Lung Cancer
Non-Small Cell Lung Cancer
Malignant Pleural Effusion
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Shofer specialize in?
Scott Shofer focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage II.
Is Scott Shofer currently recruiting for clinical trials?
Yes, Scott Shofer is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Scott Shofer has studied deeply?
Yes, Scott Shofer has studied treatments such as Talc, Biospecimen Collection, Carboplatin.
What is the best way to schedule an appointment with Scott Shofer?
Apply for one of the trials that Scott Shofer is conducting.
What is the office address of Scott Shofer?
The office of Scott Shofer is located at: Durham VA Medical Center, Durham, North Carolina 27705 United States. This is the address for their practice at the Durham VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.